

To  
The Manager (Listing)  
BSE Limited  
Phiroz JeeJeebhoy Towers,  
Dalal Street, Fort Mumbai-400001

Date: 14.11.2025

Scrip Code: 530313 [KIMIABL]

**Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.**

Respected Sir/Madam,

In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 14th November, 2025 at 7:00 P.M(IST) at the corporate office of the company ,situated at 974, 9<sup>th</sup> floor, Aggarwal Millenium Tower-II ,Netaji Subhash Place, New Delhi-110034 and the following buisnesses, amongst others, were transacted at the meeting of Board of Directors.

- 1) Approval of Unaudited financial results of the Company, on standalone basis, for the quarter and half year ended September 30<sup>th</sup> ,2025 in accordance with the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the limited Review Report issued by the Statutory Auditors of the Company.(copy attached as **Annexure A**).

The Board Meeting commenced at 07:00 PM and concluded at 08.00 PM.

This is for your kind information and record.

Thanking You

For **KIMIA BIOSCIENCES LIMITED**

Pallavi  
Garg

Digitally signed  
by Pallavi Garg  
Date: 2025.11.14  
19:52:30 +05'30'

Pallavi Garg  
Company Secretary & Compliance officer  
Place: New Delhi

**KIMIA BIOSCIENCES LIMITED**

Regd. Office/Works  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana-122102  
Tel.: +91 9654746544, 9654206544

Corporate Office  
974, 9<sup>th</sup> Floor, Aggarwal Millennium Tower-II  
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
Tel.: +91 11 47063600, 470630601



Review Report

To  
The Board of Directors  
Kimia Biosciences Limited  
Village Bhondsi, Tehsil Sohna  
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended September 30, 2025 (the "Statement") and year to date results for the period from April 01, 2025 to September 30, 2025, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Neeraj Arora & Associates  
FRN: 021309N

Neeraj Kumar Arora  
M. No. 510750  
UDIN:- 25510750BMIEJG6625  
Place:- Gurugram  
Dated:- November 14, 2025



**KIMIA BIOSCIENCES LIMITED**  
 Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102  
 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com  
 Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120



**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025**

**STATEMENT OF ASSETS, EQUITY and LIABILITIES**

| S. No.   | Particulars                               | As at<br>30-09-2025<br>(Unaudited) | As at<br>31-03-2025<br>(Audited) |
|----------|---|------------------------------------|----------------------------------|
| <b>A</b> | <b>ASSETS</b>                             |                                    |                                  |
| <b>1</b> | <b>Non-Current Assets</b>                 |                                    |                                  |
|          | Property, Plant & Equipment               | 2,954.75                           | 3,046.06                         |
|          | Capital Work-in-Progress                  | -                                  | 0.32                             |
|          | Right of Use Assets                       | 34.08                              | 43.82                            |
|          | Intangible Assets                         | 394.64                             | 237.82                           |
|          | <b>Financial Assets</b>                   |                                    |                                  |
|          | (i) Other Non Current Financial Assets    | 41.63                              | 40.88                            |
|          | Deferred Tax Assets (Net)                 | 174.02                             | 176.25                           |
|          | Other Non-current Assets                  | -                                  | 46.85                            |
| <b>2</b> | <b>Current Assets</b>                     |                                    |                                  |
|          | Inventories                               | 3,465.22                           | 3,458.31                         |
|          | <b>Financial Assets</b>                   |                                    |                                  |
|          | (i) Investment                            | -                                  | -                                |
|          | (ii) Trade Receivables                    | 2,818.30                           | 3,675.09                         |
|          | (iii) Cash and Cash Equivalents           | 20.97                              | 20.61                            |
|          | (iv) Bank balances other than (iii) above | 50.09                              | 47.49                            |
|          | (v) Other Current Financial Assets        | 112.31                             | 105.54                           |
|          | Current Tax Assets (Net)                  | 69.77                              | 67.94                            |
|          | Other Current Assets                      | 13.40                              | 154.18                           |
|          | <b>Total Assets</b>                       | <b>10,149.18</b>                   | <b>11,121.16</b>                 |


| S. No.   | Particulars  | As at<br>30-09-2025<br>(Unaudited) | As at<br>31-03-2025<br>(Audited) |
|----------|--|------------------------------------|----------------------------------|
| <b>B</b> | <b>EQUITY &amp; LIABILITIES</b>                                    |                                    |                                  |
| <b>1</b> | <b>EQUITY</b>  |                                    |                                  |
|          | (a) Share Capital  | 473.13                             | 473.13                           |
|          | (b) Other Equity   | 685.39                             | 523.48                           |
| <b>2</b> | <b>NON CURRENT LIABILITIES</b>                                     |                                    |                                  |
|          | <b>Financial Liabilities</b>                                       |                                    |                                  |
|          | (i) Borrowings   | 1,630.00                           | 1,037.01                         |
|          | (ii) Lease Liabilities   | 17.14                              | 27.59                            |
|          | (iii) Other financial liabilities                                  | -                                  | 632.97                           |
|          | Provisions   | 173.52                             | 159.67                           |
|          | Other Non-Current Liabilities                                      | -                                  | 84.81                            |
| <b>3</b> | <b>CURRENT LIABILITIES</b>   |                                    |                                  |
|          | <b>Financial Liabilities</b>                                       |                                    |                                  |
|          | (i) Borrowings   | 1,940.96                           | 2,219.62                         |
|          | (ii) Lease Liabilities   | 20.13                              | 18.62                            |
|          | (iii) Trade Payables   |                                    |                                  |
|          | a. Total Outstanding due to Micro and Small Enterprises            | 4.73                               | 4.73                             |
|          | b. Total Outstanding due to other than Micro and Small Enterprises | 4,782.13                           | 5,044.16                         |
|          | (iii) Other Financial Liabilities                                  | 434.36                             | 490.56                           |
|          | Other Current Liabilities  | (12.31)                            | 395.08                           |
|          | Provisions   | -                                  | 9.73                             |
|          | <b>Total Equity and Liabilities</b>                                | <b>10,149.18</b>                   | <b>11,121.16</b>                 |

**Other Notes**

|          |  |
|----------|--|
| <b>1</b> | The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS |
|----------|--|

Date: November 14, 2025  
 Place: New Delhi

FOR KIMIA BIOSCIENCES LIMITED  
  
 (Managing Director & CEO)  
 DIN - 00161786





**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**


(₹ Lakhs except EPS)

| S. No. | Particulars   | Quarter ended   |                 |                 | Half Year Ended |                 | Year Ended       |
|--------|---|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
|        |   | 30-09-2025      | 30-06-2025      | 30-09-2024      | 30-09-2025      | 30-09-2024      | 31-03-2025       |
|        |   | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Audited)        |
| I      | Revenue from Operations   | 3,399.93        | 2,358.41        | 2,817.86        | 5,758.34        | 5,057.79        | 11,892.08        |
| II     | Other Income  | (33.17)         | 84.69           | 37.09           | 51.52           | 45.42           | 132.03           |
| III    | <b>Total Income (I+II)</b>  | <b>3,366.76</b> | <b>2,443.10</b> | <b>2,854.95</b> | <b>5,809.86</b> | <b>5,103.21</b> | <b>12,024.11</b> |
| IV     | <b>Expenses:</b>  |                 |                 |                 |                 |                 |                  |
|        | a) Cost of materials consumed                                       | 1,771.04        | 1,706.19        | 1,746.35        | 3,477.23        | 3,243.57        | 7,455.02         |
|        | b) Change in inventories of finished goods and work-in-progress     | 474.77          | (290.32)        | (20.95)         | 184.45          | (295.52)        | (368.23)         |
|        | c) Employee benefits expenses                                       | 330.83          | 327.67          | 352.45          | 658.50          | 695.28          | 1,367.89         |
|        | d) Finance costs  | 26.70           | 174.71          | 103.93          | 201.41          | 214.77          | 455.70           |
|        | e) Depreciation and amortisation expense                            | 97.13           | 93.53           | 78.64           | 190.66          | 168.42          | 337.89           |
|        | f) Other expenses   | 571.29          | 362.18          | 403.10          | 933.47          | 707.06          | 1,412.42         |
| V      | <b>Total Expenses (IV)</b>  | <b>3,271.76</b> | <b>2,373.96</b> | <b>2,663.52</b> | <b>5,645.72</b> | <b>4,733.58</b> | <b>10,660.69</b> |
| VI     | <b>Profit/(loss) before exceptional items and Tax (III-V)</b>       | <b>95.00</b>    | <b>69.14</b>    | <b>191.43</b>   | <b>164.14</b>   | <b>369.63</b>   | <b>1,363.42</b>  |
| VII    | Exceptional Items   | -               | -               | -               | -               | -               | -                |
| VI     | <b>Profit/(loss) before tax (IV-V)</b>                              | <b>95.00</b>    | <b>69.14</b>    | <b>191.43</b>   | <b>164.14</b>   | <b>369.63</b>   | <b>1,363.42</b>  |
| VII    | <b>Tax expenses:</b>  |                 |                 |                 |                 |                 |                  |
|        | a) Current Tax  | -               | -               | 31.95           | -               | 61.69           | -                |
|        | b) Deferred Tax charge / (credit)                                   | (6.51)          | 8.74            | (1.86)          | 2.23            | 2.90            | 402.18           |
| VIII   | <b>Profit/(loss) for the period (VI-VII)</b>                        | <b>101.51</b>   | <b>60.40</b>    | <b>161.34</b>   | <b>161.91</b>   | <b>305.04</b>   | <b>961.24</b>    |
| IX     | <b>Other Comprehensive Income</b>                                   |                 |                 |                 |                 |                 |                  |
| A.     | Items that will not be reclassified to Profit or Loss (Net of Tax)  |                 |                 |                 |                 |                 |                  |
|        | - Remeasurement of defined benefit plans                            | -               | -               | -               | -               | -               | 3.04             |
| B.     | Items that will be reclassified to Profit or Loss (Net of Tax)      |                 |                 |                 |                 |                 | (0.77)           |
| X      | <b>Total Comprehensive Income for the period (VIII+IX)</b>          | <b>101.51</b>   | <b>60.40</b>    | <b>161.34</b>   | <b>161.91</b>   | <b>305.04</b>   | <b>963.51</b>    |
| XI     | Paid up equity share capital (Face value of Rs. 1 per equity share) | 473.13          | 473.13          | 473.13          | 473.13          | 473.13          | 473.13           |
| XII    | <b>Other Equity</b>   |                 |                 |                 |                 |                 |                  |
| XIII   | <b>Earnings per equity share (not annualised)</b>                   |                 |                 |                 |                 |                 |                  |
|        | Basic in Rs.  | 0.21            | 0.13            | 0.34            | 0.34            | 0.64            | 2.03             |
|        | Diluted in Rs.  | 0.21            | 0.13            | 0.34            | 0.34            | 0.64            | 2.03             |

**Other Notes**

- 1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.


**FOR KIMIA BIOSCIENCES LIMITED**



 Sameer Goel  
(Managing Director & CEO)  
DIN - 00161786

Date: November 14, 2025

Place: New Delhi



**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025****STATEMENT OF CASH FLOWS**

| Particulars  | For the half<br>year ended<br>30-09-2025<br>(Unaudited) | For the half<br>year ended<br>30-09-2024<br>(Unaudited) |
|--|---|---|
| <b>A. Cash Flow from Operating Activities</b>  |   |   |
| Net Profit / (Loss) before tax   | 164.14  | 369.63  |
| Adjustment for :   |   |   |
| Depreciation and amortization expense  | 190.66  | 168.42  |
| Finance costs  | 201.41  | 214.77  |
| Gain on fair value of investment in mutual funds   | -   | -   |
| Interest income  | (2.61)  | -   |
| Deferred revenue income  | -   | (0.68)  |
| Unrealised (gain)/loss on foreign currency transactions and translations                   | -   | -   |
| <b>Operating Profit Before Working Capital Changes</b>                                     | <b>553.60</b>   | <b>752.14</b>   |
| Adjustments for:   |   |   |
| (Increase) / Decrease in inventories   | (6.91)  | (287.57)  |
| (Increase)/ Decrease in trade and other receivables  | 993.49  | 275.05  |
| Increase/ (Decrease) in trade and other payables   | (1,405.30)  | 139.56  |
| Increase/ (Decrease) in Lease Liabilities  | (8.94)  | -   |
| <b>Cash Generated From Operations</b>  | <b>125.94</b>   | <b>879.18</b>   |
| Less : Income tax paid/ (refunds)  | (1.83)  | 2.71  |
| <b>Net Cash From Operating Activities</b>  | <b>124.11</b>   | <b>881.89</b>   |
| <b>B. Cash Flow from Investment Activities</b>   |   |   |
| Purchases of property, plant and equipments including intangible assets & capital advances | (202.70)  | (95.03)   |
| Net inflow / (outflow) in fixed deposits   | (2.60)  | (5.69)  |
| Purchase of current investments  | -   | -   |
| Interest received  | 2.61  | 0.68  |
| <b>Net Cash Used In Investing Activities</b>   | <b>(202.69)</b>   | <b>(100.04)</b>   |
| <b>C. Cash Flow from Financing Activities</b>  |   |   |
| Receipts from non current borrowings   | 547.15  | -   |
| Repayment of non current borrowings  | 45.84   | (333.55)  |
| Net proceeds of current borrowings   | (278.66)  | (192.78)  |
| Finance costs paid   | (235.39)  | (237.72)  |
| <b>Net Cash Used in Financing Activities</b>   | <b>78.94</b>  | <b>(764.05)</b>   |
| <b>Net Increase/( Decrease ) in Cash and Cash Equivalents</b>                              | <b>0.36</b>   | <b>17.81</b>  |
| Cash and Cash Equivalents at the beginning of the period                                   | 20.61   | 18.46   |
| Cash and Cash Equivalents at the end of the period   | 20.97   | 33.22   |


**Other Notes**

- I The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.

**FOR KIMIA BIOSCIENCES LIMITED**

Date: November 14, 2025

Place: New Delhi

  
**Sameer Goel**  
 (Managing Director & CEO)  
 DIN - 00161786

